Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hanall Biopharma Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current legal challenges are spread across different technical evaluations within the broader pharmaceutical field. The presence of 2 distinct art units suggests that the patent applications may cover diverse aspects of biotechnology, requiring specialized arguments for each case.
ABBAS, SYED JARAR is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending action. While there are 2 pending office actions in total, the workload is split so that 2 distinct examiners are involved. This suggests that the company must manage multiple examiner relationships simultaneously. Practitioners should be prepared for different examination styles, as the involvement of 2 distinct art units increases the likelihood of varied procedural requirements across the portfolio. Coordinating responses is essential to ensure that the 2 pending office actions do not result in conflicting claim scopes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| CHHAY, BONIRATH | 1 | 83.3% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012600 | FORMULATION FOR ANTI-FCRN ANTIBODY | CHHAY, BONIRATH | 53d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261368 | TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT | ABBAS, SYED JARAR | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261368 | TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT | ABBAS, SYED JARAR | 1674 | §103 | Final Rejection | 5d overdue | Pending | Jul 13, 2023 |
| 18012600 | FORMULATION FOR ANTI-FCRN ANTIBODY | CHHAY, BONIRATH | 1645 | §103§112DP | Final Rejection | 53d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial